Neoadjuvant mitomycin C showed a favorable safety profile with mild to moderate side effects, including hematuria, dysuria, and itchy scalp. The trial did not show significant improvement in 12-month ...

Chemoresection may be a minimally invasive option for recurrent Ta, intermediate-risk non-muscle-invasive bladder cancer (NMIBC).

Phase II study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the urothelium. Background: The response to second-line therapies in patients failing BCG is generally very ...

Phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of BCG-refractory non-muscle-invasive bladder cancer. A gene expression signature associated with sensitivity to ...

In recent years the management of non-muscle-invasive bladder cancer has undergone radical changes. Intravesical Bacillus Calmette-Guérin (BCG) has long been established as the therapeutic standard ...

In a small case series of high-risk nonmuscle-invasive bladder cancer, sequential BCG and mitomycin C, cystectomy was avoided in most cases. Sequential use of bacillus Calmette-Güerin (BCG) and ...

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, ...

In a recent randomized trial, electromotive intravesical administration of mitomycin before transurethral resection was shown to be effective in the prevention of bladder cancer recurrence. Although ...

Potential to transform care and access to treatment for this growing patient population PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to ...